SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib

被引：0
|
作者：
Ahn, M. [1 ]
Cantarini, M. [2 ]
Frewer, P. [2 ]
Hawkins, G. [2 ]
Peters, J. [2 ]
Howarth, P. [2 ]
Ahmed, G. [3 ]
Sahota, T. [3 ]
Hartmaier, R. [4 ]
Li-Sucholeiki, X. [4 ]
Oxnard, G. [5 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Astrazeneca, Cambridge, England
[3] Astrazeneca, Quantitat Clin Pharmacol, Early Clin Dev, Imed Biotech Unit, Cambridge, England
[4] Astrazeneca, Waltham, MA USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
MET; Non-Small Cell Lung Cancer; resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-134
引用
收藏
页码：S415 / S416
页数：2
相关论文
共 50 条
  • [11] A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
    Yang, J. -
    Fang, J.
    Shu, Y.
    Chang, J.
    Chen, G.
    He, J.
    Li, W.
    Liu, X.
    Yang, N.
    Zhou, C.
    Huang, J.
    Yang, L.
    Handzel, A.
    Frigault, M.
    Ahmed, G.
    Egile, C.
    Morgan, S.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1769 - S1769
  • [12] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [13] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
    Li, Meifang
    Lin, Cheng
    Lin, Jinghui
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101
  • [14] MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib plus osimertinib in EGFRm NSCLC Post-Osimertinib
    Ahn, M-J.
    De Marinis, F.
    Bonanno, L.
    Cho, B. C.
    Kim, T. -M.
    Cheng, S.
    Novello, S.
    Proto, C.
    Kim, S. -W.
    Lee, J. S.
    Metro, G.
    Yang, J. C.
    Xu, W.
    Hartmaier, R.
    Telaranta-Keerie, A.
    Poole, L.
    Sequist, L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S469 - S470
  • [15] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
    Smit, E.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
  • [16] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [17] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [18] Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC
    Aguilar, A.
    Cobo, M.
    Azkarate, A.
    Calles, A.
    Molina, M. A.
    Rosell, R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S401 - S402
  • [19] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [20] Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Kim, C.
    Liu, S.
    Subramaniam, D.
    Giaccone, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S479 - S479
12345